Research programme: radiolabeled imaging agents- Bioverativ/ Invicro

Drug Profile

Research programme: radiolabeled imaging agents- Bioverativ/ Invicro

Latest Information Update: 16 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioverativ; Invicro
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Haemophilia

Most Recent Events

  • 24 Aug 2017 Bioverativ and Invicro agree to co-develop radiolabeled imaging technologies in USA for Haemophilia (Diagnosis)
  • 24 Aug 2017 Research in Haemophilia (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top